{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:49:22Z","timestamp":1767890962173,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study is based on the QbD development of extended-release (ER) extruded-spheronized pellets of Meclizine HCl and its comparative pharmacokinetic evaluation with immediate-release (IR) pellets. HPLC-fluorescence method was developed and validated for plasma drug analysis. IR drug cores were prepared from lactose, MCC, and PVP using water as granulating fluid. Three-level, three-factor CCRD was applied for modeling and optimization to study the influence of Eudragit (RL100-RS100), TEC, and talc on drug release and sphericity of coated pellets. HPLC-fluorescence method was sensitive with LLOQ 1\u00a0ng\/ml and linearity between 10 and 200\u00a0ng\/ml with R<jats:sup>2<\/jats:sup>\u2009&gt;\u20090.999. Pharmacokinetic parameters were obtained by non-compartmental analysis and results were statistically compared using logarithmically transformed data, where p\u2009&gt;\u20090.05 was considered as non-significant with a 90% CI limit of 0.8\u20131.25. The AUC<jats:sub>0\u2013t<\/jats:sub> and AUC<jats:sub>0\u2013\u221e<\/jats:sub> of ER pellets were not significantly different with geometric mean ratio 1.0096 and 1.0093, respectively. The C<jats:sub>max<\/jats:sub> of IR pellets (98.051\u00a0ng\/ml) was higher than the ER pellets (84.052\u00a0ng\/ml) and the T<jats:sub>max<\/jats:sub> of ER pellets (5.116\u00a0h) was higher than the IR pellets (3.029\u00a0h). No significant food effect was observed on key pharmacokinetic parameters of ER pellets. Eudragit RL100 (6%) coated Meclizine HCl pellets have a potential therapeutic effect for an extended time period.<\/jats:p>","DOI":"10.1038\/s41598-020-71751-y","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:03:14Z","timestamp":1599732194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["QbD based Eudragit coated Meclizine HCl immediate and extended release multiparticulates: formulation, characterization and pharmacokinetic evaluation using HPLC-Fluorescence detection method"],"prefix":"10.1038","volume":"10","author":[{"given":"Faaiza","family":"Qazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Harris","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia Ismail","family":"Yousuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Iqbal","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iyad Naeem","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrukh Rafiq","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"71751_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12944-017-0466-x","volume":"16","author":"F Qazi","year":"2017","unstructured":"Qazi, F. et al. Lipids bearing extruded-spheronized pellets for extended-release of poorly soluble antiemetic agent\u2014Meclizine HCl. Lipids Health Dis. 16, 75. https:\/\/doi.org\/10.1186\/s12944-017-0466-x (2017).","journal-title":"Lipids Health Dis."},{"key":"71751_CR2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0091270011414575","volume":"52","author":"Z Wang","year":"2012","unstructured":"Wang, Z. et al. Meclizine metabolism and pharmacokinetics: Formulation on its absorption. J. Clin. Pharmacol. 52, 1343\u20131349 (2012).","journal-title":"J. Clin. Pharmacol."},{"key":"71751_CR3","first-page":"141","volume":"34","author":"GM Mahrous","year":"2011","unstructured":"Mahrous, G. M., Shazly, G. A. & Ibrahim, M. A. Formulation and evaluation of meclizine HCl orally disintegrating tablets. Bull. Pharm. Sci. 34, 141\u2013148 (2011).","journal-title":"Bull. Pharm. Sci."},{"key":"71751_CR4","unstructured":"Pfizer Products Antivert. (Accessed 10 Apr 2018). https:\/\/www.pfizerpro.com\/pfizer-products."},{"key":"71751_CR5","unstructured":"EvonikProducts Eudragit. Eudragitfunctional polymers for sustained release (Accessed 11 February 2017). https:\/\/healthcare.evonik.com\/product\/health-care\/en\/products\/pharmaceutical-excipients\/time-controlled-release\/pages\/default.aspx."},{"key":"71751_CR6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1021\/ac60343a024","volume":"46","author":"DR Wirz","year":"1974","unstructured":"Wirz, D. R., Wilson, D. L. & Schenk, G. H. Fluorescence and phosphorescence of antihistamines having the diphenylmethane chromophore. Effect of halide ions on luminescence. Anal. Chem. 46, 896\u2013900 (1974).","journal-title":"Anal. Chem."},{"key":"71751_CR7","first-page":"102","volume":"3","author":"HM Younis","year":"2014","unstructured":"Younis, H. M. & Omara, H. A. Spectrophotometric micro determination of meclizine hydrochloride in their pharmaceutical formulations and spiked plasma. World J. Pharm. Pharmaceut. Sci. 3, 102\u2013112 (2014).","journal-title":"World J. Pharm. Pharmaceut. Sci."},{"key":"71751_CR8","first-page":"516","volume":"3","author":"HA Omara","year":"2014","unstructured":"Omara, H. A. New spectrophotometric micro determination of meclizine Hcl in pharmaceutical formulations and human plasma. IJAPBC 3,\n516\u2013522 (2014).","journal-title":"IJAPBC"},{"key":"71751_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1365\/s10337-008-0615-5","volume":"67","author":"MS Arayne","year":"2008","unstructured":"Arayne, M. S., Sultana, N. & Siddiqui, F. A. Simultaneous determination of pyridoxine, meclizine, and buclizine in dosage formulations and human serum by RP-LC. Chromatographia 67, 941\u2013945 (2008).","journal-title":"Chromatographia"},{"key":"71751_CR10","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1039\/c3ay41698d","volume":"6","author":"N Sher","year":"2014","unstructured":"Sher, N. et al. Simultaneous determination of antihistamine anti-allergic drugs, cetirizine, domperidone, chlorphenamine maleate, loratadine, meclizine, and buclizine in pharmaceutical formulations, human serum, and pharmacokinetics application. Anal. Methods 6, 2704\u20132714 (2014).","journal-title":"Anal. Methods"},{"key":"71751_CR11","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1080\/01483918708068931","volume":"10","author":"T Imai","year":"1987","unstructured":"Imai, T. et al. Quantitation of meclizine dihydrochloride in serum by reversed-phase ion-pair high-performance liquid chromatography. J. Liq. Chromatogr. 10, 2505\u20132512 (1987).","journal-title":"J. Liq. Chromatogr."},{"key":"71751_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jchromb.2010.11.022","volume":"879","author":"Z Wang","year":"2011","unstructured":"Wang, Z., Qian, S., Zhang, Q. & Chow, M. S. Quantification of meclizine in human plasma by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 95\u201399. https:\/\/doi.org\/10.1016\/j.jchromb.2010.11.022 (2011).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"71751_CR13","first-page":"027","volume":"8","author":"R Kharshoum","year":"2016","unstructured":"Kharshoum, R. & Aboutaleb, H. Formulation, development, and evaluation of meclozine hydrochloride microspheres. J. Bioequiv. Availab. 8, 027\u2013032 (2016).","journal-title":"J. Bioequiv. Availab."},{"key":"71751_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ijpharm.2015.10.008","volume":"496","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y., Quan, P. & Fang, L. Preparation of an oral thin film containing meclizine hydrochloride: In vitro and in vivo evaluation. Int. J. Pharm. 496, 314\u2013322. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.10.008 (2015).","journal-title":"Int. J. Pharm."},{"key":"71751_CR15","unstructured":"FDA. Bioanalytical Method Validation: Guidance for Industry (Accessed 27 June 2018). https:\/\/www.fda.gov\/media\/70858\/download."},{"key":"71751_CR16","unstructured":"ICH Guidelines. ICH Q2 (R1) Validation of analytical procedures: Text and methodology (Accessed 25 June 2018). https:\/\/www.ema.europa.eu\/en\/ich-q2-r1-validation-analytical-procedures-text-methodology. (1995)."},{"key":"71751_CR17","unstructured":"EvonikProducts Eudragit. Technical Information-Quick start, Eudragit RL 100 and\/or RS 100: Organic sustained-release coating (Accessed 06 Jan 2020). https:\/\/studylib.net\/doc\/18093309\/Eudragit-rl-100-and-or-rs-100-organic-sustained-release. (2020)."},{"key":"71751_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejpb.2006.08.015","volume":"66","author":"A Duki\u0107","year":"2007","unstructured":"Duki\u0107, A. et al. Development of starch-based pellets via extrusion\/spheronisation. Eur. J. Pharm. Biopharm. 66, 83\u201394 (2007).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"71751_CR19","unstructured":"Jones, B. E. Hard capsules in Aulton\u2019s pharmaceutics. In The Design and Manufacture of Medicines. (eds Aulton, M. E., & Taylor, K. M. G.) 597\u2013611\n(Elsevier, 2018)."},{"key":"71751_CR20","volume-title":"The United States Pharmacopeia and The National Formulary (USP\u2013NF)","author":"USP39-NF34","year":"2016","unstructured":"USP39-NF34. The United States Pharmacopeia and The National Formulary (USP\u2013NF) (The US Pharmacopeial Convention (USP) Inc., Rockville, 2016)."},{"key":"71751_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.powtec.2012.08.019","volume":"233","author":"B Chamsai","year":"2013","unstructured":"Chamsai, B. & Sriamornsak, P. Novel disintegrating microcrystalline cellulose pellets with improved drug dissolution performance. Powder Technol. 233, 278\u2013285 (2013).","journal-title":"Powder Technol."},{"key":"71751_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0378-5173(99)00302-6","volume":"192","author":"F Podczeck","year":"1999","unstructured":"Podczeck, F., Rahman, S. & Newton, J. Evaluation of a standardized procedure to assess the shape of pellets using image analysis. Int. J. Pharm. 192, 123\u2013138 (1999).","journal-title":"Int. J. Pharm."},{"key":"71751_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ces.2012.04.037","volume":"86","author":"T Kitak","year":"2013","unstructured":"Kitak, T., Govedarica, B. & Sr\u010di\u010d, S. Physical properties of pharmaceutical pellets. Chem. Eng. Sci. 86, 50\u201360 (2013).","journal-title":"Chem. Eng. Sci."},{"key":"71751_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0928-0987(02)00260-9","volume":"18","author":"CC Larsen","year":"2003","unstructured":"Larsen, C. C., Sonnergaard, J. M., Bertelsen, P. & Holm, P. Validation of an image analysis method for estimating coating thickness on pellets. Eur. J. Pharm. Sci. 18, 191\u2013196 (2003).","journal-title":"Eur. J. Pharm. Sci."},{"key":"71751_CR25","unstructured":"ICH Guidelines. Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products (Accessed 06 Jan 2017). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q1ar2-stability-testing-new-drug-substances-and-products. (2003)."},{"key":"71751_CR26","unstructured":"FDA guidelines. Statistical Approaches to Establishing Bioequivalence (Accessed 29 May 2018). https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070244.pdf. (2001)."},{"key":"71751_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpb.2008.08.005","volume":"71","author":"A Duki\u0107-Ott","year":"2009","unstructured":"Duki\u0107-Ott, A., Thommes, M., Remon, J. P., Kleinebudde, P. & Vervaet, C. Production of pellets via extrusion\u2013spheronisation without the incorporation of microcrystalline cellulose: A critical review. Eur. J. Pharm. Biopharm. 71, 38\u201346. https:\/\/doi.org\/10.1016\/j.ejpb.2008.08.005 (2009).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"71751_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijpharm.2005.07.016","volume":"303","author":"MR Abbaspour","year":"2005","unstructured":"Abbaspour, M. R., Sadeghi, F. & Garekani, H. A. Preparation and characterization of ibuprofen pellets based on Eudragit RS PO and RL PO or their combination. Int. J. Pharm. 303, 88\u201394. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.07.016 (2005).","journal-title":"Int. J. Pharm."},{"key":"71751_CR29","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1208\/ps020324","volume":"2","author":"J Kristensen","year":"2000","unstructured":"Kristensen, J., Schaefer, T. & Kleinebudde, P. Direct pelletization in a rotary processor controlled by torque measurements. II: Effects of changes in the content of microcrystalline cellulose. AAPS PharmSci. 2, E24 (2000).","journal-title":"AAPS PharmSci."},{"key":"71751_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i3.20","volume":"26","author":"VR Sinha","year":"2009","unstructured":"Sinha, V. R., Agrawal, M. K., Agarwal, A., Singh, G. & Ghai, D. Extrusion-spheronization: Process variables and characterization. Crit. Rev. Ther. Drug Carrier Syst. 26, 275\u2013331 (2009).","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"71751_CR31","first-page":"425","volume":"27","author":"S Karim","year":"2014","unstructured":"Karim, S., Baie, S. H., Hay, Y. K. & Bukhari, N. I. Development and evaluation of omeprazole pellets fabricated by sieving-spheronization and extrusion\u2014Spheronization process. Pak. J. Pharm. Sci. 27, 425\u2013438 (2014).","journal-title":"Pak. J. Pharm. Sci."},{"key":"71751_CR32","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3109\/03639045.2012.707207","volume":"39","author":"HA Garekani","year":"2013","unstructured":"Garekani, H. A., Nokhodchi, A., Rayeni, M. A. & Sadeghi, F. Preparation and characterization and release properties of Eudragit RS based ibuprofen pellets prepared by extrusion spheronization: effect of binder type and concentration. Drug Dev. Ind. Pharm. 39, 1238\u20131246 (2013).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"71751_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ajps.2013.09.007","volume":"8","author":"X Han","year":"2013","unstructured":"Han, X. et al. Preparation and evaluation of sustained-release diltiazem hydrochloride pellets. Asian J. Pharm. Sci. 8, 244\u2013251. https:\/\/doi.org\/10.1016\/j.ajps.2013.09.007 (2013).","journal-title":"Asian J. Pharm. Sci."},{"key":"71751_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0168-3659(99)00193-5","volume":"63","author":"KA Mehta","year":"2000","unstructured":"Mehta, K. A., Kislalioglu, M. S., Phuapradit, W., Malick, A. W. & Shah, N. H. Effect of formulation and process variables on porosity parameters and release rates from a multi-unit erosion matrix of a poorly soluble drug. J Control Release. 63, 201\u2013211 (2000).","journal-title":"J Control Release."},{"key":"71751_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijpharm.2006.09.041","volume":"332","author":"ARC Duarte","year":"2007","unstructured":"Duarte, A. R. C., Roy, C., Vega-Gonz\u00e1lez, A., Duarte, C. M. & Subra-Paternault, P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int. J. Pharm. 332, 132\u2013139 (2007).","journal-title":"Int. J. Pharm."},{"key":"71751_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jfda.2014.05.001","volume":"22","author":"PK Gaur","year":"2014","unstructured":"Gaur, P. K., Mishra, S. & Bajpai, M. Formulation and evaluation of controlled-release of telmisartan microspheres: In vitro\/in vivo study. J. Food Drug Anal. 22, 542\u2013548 (2014).","journal-title":"J. Food Drug Anal."},{"key":"71751_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1517\/17425247.2013.736962","volume":"10","author":"S Thakral","year":"2013","unstructured":"Thakral, S., Thakral, N. K. & Majumdar, D. K. Eudragit: A technology evaluation. Expert Opin. Drug Deliv. 10, 131\u2013149. https:\/\/doi.org\/10.1517\/17425247.2013.736962 (2013).","journal-title":"Expert Opin. Drug Deliv."},{"key":"71751_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/157015910790909511","volume":"8","author":"E Soto","year":"2010","unstructured":"Soto, E. & Vega, R. Neuropharmacology of vestibular system disorders. Curr. Neuropharmacol. 8, 26\u201340 (2010).","journal-title":"Curr. Neuropharmacol."},{"key":"71751_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jchromb.2005.05.007","volume":"821","author":"Z Zeng","year":"2005","unstructured":"Zeng, Z., Dong, A., Yang, G., Chen, Z. & Huang, X. Simultaneous determination of nine fluoroquinolones in egg white and egg yolk by liquid chromatography with fluorescence detection. J. Chromatogr. B. 821, 202\u2013209 (2005).","journal-title":"J. Chromatogr. B."},{"key":"71751_CR40","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.aca.2008.04.012","volume":"616","author":"G-W Cheng","year":"2008","unstructured":"Cheng, G.-W., Wu, H.-L. & Huang, Y.-L. Simultaneous determination of malondialdehyde and ofloxacin in plasma using an isocratic high-performance liquid chromatography\/fluorescence detection system. Anal. Chim. Acta. 616, 230\u2013234 (2008).","journal-title":"Anal. Chim. Acta."},{"key":"71751_CR41","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.jchromb.2010.04.012","volume":"878","author":"S Watabe","year":"2010","unstructured":"Watabe, S. et al. Simultaneous measurement of pazufloxacin, ciprofloxacin, and levofloxacin in human serum by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B. 878, 1555\u20131561 (2010).","journal-title":"J. Chromatogr. B."},{"key":"71751_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.clinthera.2010.01.026","volume":"32","author":"SB Jang","year":"2010","unstructured":"Jang, S. B. et al. Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single-and multiple-dose study. Clin. Ther. 32, 206\u2013216 (2010).","journal-title":"Clin. Ther."},{"key":"71751_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/DDDT.S53027","volume":"8","author":"S Yoon","year":"2014","unstructured":"Yoon, S. et al. Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers. Drug Des. Dev. Ther. 8, 123 (2014).","journal-title":"Drug Des. Dev. Ther."},{"key":"71751_CR44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.addr.2007.08.043","volume":"60","author":"JM Custodio","year":"2008","unstructured":"Custodio, J. M., Wu, C.-Y. & Benet, L. Z. Predicting drug disposition, absorption\/elimination\/transporter interplay, and the role of food on drug absorption. Adv. Drug Deliver. Rev. 60, 717\u2013733 (2008).","journal-title":"Adv. Drug Deliver. Rev."},{"key":"71751_CR45","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1023\/A:1014407421366","volume":"19","author":"ES Kostewicz","year":"2002","unstructured":"Kostewicz, E. S., Brauns, U., Becker, R. & Dressman, J. B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res. 19, 345\u2013349 (2002).","journal-title":"Pharm. Res."},{"key":"71751_CR46","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/jps.22122","volume":"99","author":"K Kleberg","year":"2010","unstructured":"Kleberg, K., Jacobsen, F., Fatouros, D. G. & M\u00fcllertz, A. Biorelevant media simulating fed state intestinal fluids: Colloid phase characterization and impact on solubilization capacity. J. Pharm. Sci. 99, 3522\u20133532 (2010).","journal-title":"J. Pharm. Sci."},{"key":"71751_CR47","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1136\/gut.27.8.886","volume":"27","author":"S Davis","year":"1986","unstructured":"Davis, S., Hardy, J. & Fara, J. Transit of pharmaceutical dosage forms through the small intestine. Gut 27, 886\u2013892 (1986).","journal-title":"Gut"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71751-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71751-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71751-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:19:32Z","timestamp":1670350772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71751-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71751"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71751-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"31 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14765"}}